Logo

American Heart Association

  2
  0


Final ID: MDP1617

An Echocardiogram-Based Risk Model to Predict Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study

Abstract Body (Do not enter title and authors here): Background: Atrial fibrillation (AF) is often asymptomatic and detection of AF is challenging. 2D-Echocardiogram (2DE) provides a comprehensive assessment of cardiac structure and function, and hence, may be used to predict AF.
Aim: To derive a 2DE-based risk model to predict AF using supervised machine learning (ML).
Methods: We included 5,445 older adults from the Atherosclerosis Risk in Communities (ARIC) study who underwent transthoracic 2DE at baseline (visit 5, 2011-2013) and had no known history of AF. Individuals were randomly allocated to the training and testing sets in a 7:3 ratio. Incident AF was ascertained from hospitalization records and death certificate during follow-up. Missing values of 2DE measures with <10% missingness were imputed 50 times via Multiple Imputation by Chained Equations (MICE), and those with ≥10% missingness were excluded from the analysis. The Lasso approach was used for variable selection based on the consensus of the 50 imputed datasets. Significant variables (P<0.05) were used to build a model for prediction of incident AF in the training set by Cox proportional hazards regression. Harrell’s C-index was used to assess model performance.
Results: The median (IQR) age was 74 (71-79) years (59% female, 23% Black). During a median (IQR) follow-up of 7.0 (5.4-7.8) years, 738 participants developed AF. The cumulative incidence of AF was 1.4%, 5.0%, and 9.6% at 1, 3, 5 years, respectively. The table shows the hazard ratios for AF of each predictor in the final model. The Harrell’s C-index at 1-, 3-, and 5-year was 0.80, 0.72, and 0.73, respectively in the training set and was 0.76, 0.74, and 0.75, respectively in the testing set.
Conclusion: Our ML derived 2DE-based risk model has good model discrimination for prediction of AF, setting the stage for a deep learning model using 2DE images for AF prediction.
  • Sun, Daokun  ( University of Minnesota , Minneapolis , Minnesota , United States )
  • Chen, Lin  ( UNIVERSITY OF MINNESOTA , Minneapolis , Minnesota , United States )
  • Chan, Lap Sum  ( University of Minnesota , Minneapolis , Minnesota , United States )
  • Norby, Faye  ( University of Minnesota , Minneapolis , Minnesota , United States )
  • Inciardi, Riccardo  ( BWH , Boston , Massachusetts , United States )
  • Soliman, Elsayed  ( WAKE FOREST SCHOOL OF MEDICINE , Winston Salem , North Carolina , United States )
  • Alonso, Alvaro  ( Emory University , Atlanta , Georgia , United States )
  • Solomon, Scott  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Shah, Amil  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Pan, Wei  ( University of Minnesota , Minneapolis , Minnesota , United States )
  • Author Disclosures:
    Daokun Sun: DO NOT have relevant financial relationships | Lin Chen: DO NOT have relevant financial relationships | Lap Sum Chan: DO NOT have relevant financial relationships | Faye Norby: DO NOT have relevant financial relationships | Riccardo Inciardi: DO NOT have relevant financial relationships | Elsayed Soliman: DO NOT have relevant financial relationships | Alvaro Alonso: DO NOT have relevant financial relationships | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now) | Amil Shah: DO have relevant financial relationships ; Advisor:Philips Ultrasound:Past (completed) ; Advisor:Janssen:Past (completed) | Wei Pan: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Know the Score: Cardiovascular Disease Risk Prediction

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A novel risk score predicts the prevalence of left atrial low-voltage areas and rhythm outcome in patients undergoing long-standing persistent atrial fibrillation ablation

Ooka Hirotaka, Nakao Sho, Kusuda Masaya, Ariyasu Wataru, Kudo Satoshi, Fujii Subaru, Mano Toshiaki, Matsuda Yasuhiro, Masuda Masaharu, Okamoto Shin, Ishihara Takayuki, Nanto Kiyonori, Tsujimura Takuya, Hata Yosuke, Uematsu Hiroyuki

A RETROSPECTIVE EVALUATION OF RESOURCE UTILIZATION AND OUTCOMES IN PATIENTS USING MOBILE ECG DEVICES FOLLOWING ABLATION FOR ATRIAL FIBRILLATION

Fairman Alix, Loh Alexander, Druml Lauren, Triplett Cynthia, Liu Taylor, Pursnani Seema

More abstracts from these authors:
Resting Heart Rate Trajectories over 25 Years: Patterns, Predictors, and Prognostic Impact in the Atherosclerosis Risk in Communities (ARIC) Study

Meng Ning, Mok Yejin, Soliman Elsayed, Chen Lin, Ballantyne Christie, Solomon Scott, Matsushita Kuni

Differential Association of Atrial Myopathy Subtypes with Incident Atrial Fibrillation: The Atherosclerosis Risk in Communities Study (ARIC)

Moser Ethan, Shah Amil, Pan Wei, Chen Lin, He Ruoyu, Wang Wendy, Van't Hof Jeremy, Sun Daokun, Zhang Chunxiao, Zhang Michael, Chan Lap Sum, Solomon Scott

You have to be authorized to contact abstract author. Please, Login
Not Available